Updated Monday, October 22, 2018
 Journal Tools
RSS Feed
Sample Copy
Submit a Manuscript
Contact Us
Subscription
Advertising
Thanking Peer Reviewers
 Language Polishing
Journal of Integrative Medicine: Volume 11, 2013   Issue 4,  Pages: 233-240

DOI: 10.3736/jintegrmed2013037
Review
Research advances on the usage of traditional Chinese medicine for neuroprotection in glaucoma
1. Xue-song Mi (Department of Ophthalmology, the First Affiliated Hospital, Jinan University, Guangzhou 510630, Guangdong Province, China )
2. Jing-xiang Zhong (Department of Ophthalmology, the First Affiliated Hospital, Jinan University, Guangzhou 510630, Guangdong Province, China )
3. Raymond Chuen-Chung Chang (Department of Anatomy, and the State Key Laboratory of Brain and Cognitive Science, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China )
4. Kwok-Fai So (Department of Anatomy, and the State Key Laboratory of Brain and Cognitive Science, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China E-mail: hrmaskf@hkucc.hku.hk)

ABSTRACT: Progressive loss of retinal ganglion cells (RGCs) and their axons is the main pathogenesis of glaucoma. The cause of glaucoma is not fully understood, but the neurodegeneration of glaucoma involves many mechanisms such as oxidative stress, glutamate toxicity and ischemia/reperfusion insult. In order to target these mechanisms, multiple neuroprotective interventions have been investigated to prevent the death of RGCs. Of note are some tonic herbs from the traditional Chinese medicine (TCM) pharmacopeia that have shown neuroprotective effects in glaucoma. TCM differs from Western medicine in that TCM exhibits complicated bioactive components, triggering many signaling pathways and extensive actions on vital organs. Modern scientific approaches have demonstrated some of their underlying mechanisms. In this review, we used Lycium barbarum and Ginkgo biloba as examples to elaborate the characteristics of TCM and their potential applications in neuroprotection in glaucoma.

Welcome to JIM! You are the number 34582 reader of this article!
Download Article:
[Full Text]      [PDF]      [Previous]      [Next]      [This Issue]
Please cite this article as:
Mi XS, Zhong JX, Chang RCC, So KF. Research advances on the usage of traditional Chinese medicine for neuroprotection in glaucoma. J Integr Med. 2013; 11(4): 233-240.
References:
1Foster PJ, Johnson GJ. Glaucoma in China: how big is the problem? Br J Ophthalmol. 2001; 85(11): 1277-1282.
2Quigley HA. Glaucoma[J].Lancet, 2011, 377(9774): 1367-1377.  
3Quigley HA. Clinical trials for glaucoma neuroprotection are not impossible[J].Curr Opin Ophthalmol, 2012, 23(2): 144-154.  
4McKinnon SJ. Glaucoma: ocular Alzheimer’s disease[J].Front Biosci, 2003, 8: s1140-s1156.  
5Flammer J, Orgül S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, Renard JP, Stefánsson E. The impact of ocular blood flow in glaucoma[J].Prog Retin Eye Res, 2002, 21(4): 359-393.  
6Vingrys AJ. The many faces of glaucomatous optic neuropathy[J].Clin Exp Optom, 2000, 83(3): 145-160.  
7Almasieh M, Wilson AM, Morquette B, Cueva Vargas JL, Di Polo A. The molecular basis of retinal ganglion cell death in glaucoma[J].Prog Retin Eye Res, 2012, 31(2): 152-181.  
8Chader GJ. Advances in glaucoma treatment and management: neurotrophic agents[J].Invest Ophthalmol Vis Sci, 2012, 53(5): 2501-2505.  
9Nakatani M, Shinohara Y, Takii M, Mori H, Asai N, Nishimura S, Furukawa-Hibi Y, Miyamoto Y, Nitta A. Periocular injection of in situ hydrogels containing Leu-Ile, an inducer for neurotrophic factors, promotes retinal ganglion cell survival after optic nerve injury[J].Exp Eye Res, 2011, 93(6): 873-879.  
10Parrilla-Reverter G, Agudo M, Sobrado-Calvo P, Salinas-Navarro M, Villegas-Pérez MP, Vidal-Sanz M. Effects of different neurotrophic factors on the survival of retinal ganglion cells after a complete intraorbital nerve crush injury: a quantitative in vivo study. Exp Eye Res; 2009; 89(1): 32-41.
11Wen R, Tao W, Li Y, Sieving PA. CNTF and retina[J].Prog Retin Eye Res, 2012, 31(2): 136-151.  
12Zhou X, Xia XB, Xiong SQ. Neuro-protection of retinal stem cells transplantation combined with copolymer-1 immunization in a rat model of glaucoma[J].Mol Cell Neurosci, 2013, 54: 1-8.  
13Harper MM, Grozdanic SD, Blits B, Kuehn MH, Zamzow D, Buss JE, Kardon RH, Sakaguchi DS. Transplantation of BDNF-secreting mesenchymal stem cells provides neuroprotection in chronically hypertensive rat eyes[J].Invest Ophthalmol Vis Sci, 2011, 52(7): 4506-4515.  
14Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma[J].Arch Ophthalmol, 1996, 114(3): 299-305.  
15Giulian D. Reactive glia as rivals in regulating neuronal survival[J].Glia, 1993, 7(1): 102-110.  
16Vorwerk CK, Lipton SA, Zurakowski D, Hyman BT, Sabel BA, Dreyer EB. Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine[J].Invest Ophthalmol Vis Sci, 1996, 37(8): 1618-1624.  
17Siliprandi R, Canella R, Carmignoto G, Schiavo N, Zanellato A, Zanoni R, Vantini G. N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina[J].Vis Neurosci, 1992, 8(6): 567-573.  
18Ahmed FA, Hegazy K, Chaudhary P, Sharma SC. Neuroprotective effect of α2 agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure[J].Brain Res, 2001, 913(2): 133-139.  
19Sacca S. Nitric oxide as a mediator of glaucoma pathogenesis[J].Med Sci Monit, 2002, 8(8): LE33-LE34.  
20Aslan M, Cort A, Yucel I. Oxidative and nitrative stress markers in glaucoma[J].Free Radic Biol Med, 2008, 45(4): 367-376.  
21Siu AW, Leung MC, Ho To C, Siu FK, Ji J, So KF. Total retinal nitric oxide production is increased in intraocular pressure-elevated rats[J].Exp Eye Res, 2002, 75(4): 401-406.  
22Neufeld AH, Shareef S, Pena J. Cellular localization of neuronal nitric oxide synthase (NOS-1) in the human and rat retina[J].J Comp Neurol, 2000, 416(2): 269-275.  
23Nucci C, Morrone L, Rombolà L, Nisticò R, Piccirilli S, Cerulli L. Multifaceted roles of nitric oxide in the lateral geniculate nucleus: from visual signal transduction to neuronal apoptosis[J].Toxicol Lett, 2003, 139(2-3): 163-173.  
24Liu B, Neufeld AH. Nitric oxide synthase-2 in human optic nerve head astrocytes induced by elevated pressure in vitro[J].Arch Ophthalmol, 2001, 119(2): 240-245.  
25Klein C. Nitric oxide and the other cyclic nucleotide[J].Cell Signal, 2002, 14(6): 493-498.  
26Groc L, Jackson Hunter T, Jiang H, Bezin L, Koubi D, Corcoran GB, Levine RA. Nitric oxide synthase inhibition during development: effect on apoptotic death of dopamine neurons[J].Brain Res Dev Brain Res, 2002, 138(2): 147-153.  
27Baltmr A, Duggan J, Nizari S, Salt TE, Cordeiro MF. Neuroprotection in glaucoma — Is there a future role? Exp Eye Res. 2010; 91(5): 554-566.
28Danesh-Meyer HV. Neuroprotection in glaucoma: recent and future directions[J].Curr Opin Ophthalmol, 2011, 22(2): 78-86.  
29Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension[J].Ther Clin Risk Manag, 2006, 2(4): 337-346.  
30Osborne NN. Pathogenesis of ganglion “cell death” in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria[J].Prog Brain Res, 2008, 173: 339-352.  
31Ho YS, So KF, Chang RC. Drug discovery from Chinese medicine against neurodegeneration in Alzheimer’s and vascular dementia[J].Chin Med, 2011, 6: 15.  
32Chang RC, So KF. Use of anti-aging herbal medicine, Lycium barbarum, against aging-associated diseases[J].What do we know so far? Cel Mol Neurobiol, 2008, 28(5): 643-652.  
33Luo Q, Cai Y, Yan J, Sun M, Corke H. Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts from Lycium barbarum[J].Life Sci, 2004, 76(2): 137-149.  
34Jin M, Huang Q, Zhao K, Shang P. Biological activities and potential health benefit effects of polysaccharides isolated from Lycium barbarum L[J].Int J Biol Macromol, 2013, 54: 16-23.  
35Yu MS, Leung SK, Lai SW, Che CM, Zee SY. Neuroprotective effects of anti-aging oriental medicine Lycium barbarum against β-amyloid peptide neurotoxicity[J].Exp Gerontol, 2005, 40: 716-727.  
36Ho YS, Yu MS, Yik SY, So KF, Yuen WH, Chang RCC. Polysaccharides from wolfberry antagonizes glutamate excitotoxicity in rat cortical neurons[J].Cell Mol Neurobiol, 2009, 29(8): 1233-1244.  
37Chiu K, Zhou Y, Yeung SC, Lok CK, Chan OO, Chang RC, So KF, Chiu JF. Up-regulation of crystallins is involved in the neuroprotective effect of wolfberry on survival of retinal ganglion cells in rat ocular hypertension model[J].J Cell Biochem, 2010, 110(2): 311-320.  
38Chan HC, Chang RC, Koon-Ching Ip A, Chiu K, Yuen WH, Zee SY, So KF. Neuroprotective effects of Lycium barbarum Lynn on protecting retinal ganglion cells in an ocular hypertension model of glaucoma[J].Exp Neurol, 2007, 203(1): 269-273.  
39Li SY, Yeung CM, Yu WY, Chang RC, So KF, Wong D, Lo AC. Lycium barbarum polysaccharides reduce neuronal damage, blood-retinal barrier disruption and oxidative stress in retinal ischemia/reperfusion injury[J].PLoS One, 2011, 6(1): e16380.  
40Ho YS, So KF, Chang RC. Anti-aging herbal medicine — How and why can they be used in aging-associated neurodegenerative diseases? Ageing Res Rev. 2010; 9(3): 354-362.
41Chiu K, Chan HC, Yeung SC, Yuen WH, Zee SY, Chang RC, So KF. Modulation of microglia by Wolfberry on the survival of retinal ganglion cells in a rat ocular hypertension model[J].J Ocul Biol Dis Infor, 2009, 2(3): 127-136.  
42Tezel G. Immune regulation toward immunomodulation for neuroprotection in glaucoma[J].Curr Opin Pharmacol, 2013, 13(1): 23-31.  
43Tezel G, Thornton IL, Tong MG, Luo C, Yang X, Cai J, Powell DW, Soltau JB, Liebmann JM, Ritch R. Immunoproteomic analysis of potential serum biomarker candidates in human glaucoma[J].Invest Ophthalmol Vis Sci, 2012, 53(13): 8222-8231.  
44Moalem G, Monsonego A, Shani Y, Cohen IR, Schwartz M. Differential T cell response in central and peripheral nerve injury: connection with immune privilege[J].FASEB J, 1999, 13(10): 1207-1217.  
45Barouch R, Schwartz M. Autoreactive T cells induce neurotrophin production by immune and neural cells in injured rat optic nerve: implications for protective autoimmunity[J].FASEB J, 2002, 16(10): 1304-1306.  
46Bosco A, Steele MR, Vetter ML. Early microglia activation in a mouse model of chronic glaucoma[J].J Comp Neurol, 2011, 519(4): 599-620.  
47Gan L, Zhang SH, Liu Q, Xu HB. A polysaccharide-protein complex from Lycium barbarum upregulates cytokine expression in human peripheral blood mononuclear cells[J].Eur J Pharmacol, 2003, 471(3): 217-222.  
48Yu MS, Ho YS, So KF, Yuen WH, Chang RC. Cytoprotective effects of Lycium barbarum against reducing stress on endoplasmic reticulum[J].Int J Mol Med, 2006, 17(6): 1157-1161.  
49Krishnamoorthy RR, Rao VR, Dauphin R, Prasanna G, Johnson C, Yorio T. Role of the ETB receptor in retinal ganglion cell death in glaucoma[J].Can J Physiol Pharmacol, 2008, 86(6): 380-393.  
50Mi XS, Chiu K, Van G, Leung JWC, Lo AC, Chung SK, Chang RC, So KF. Effect of Lycium barbarum polysaccharides on the expression of endothelin-1 and its receptors in an ocular hypertension model of rat glaucoma[J].Neural Regen Res, 2012, 7(9): 645-651.  
51Mi XS, Feng Q, Lo AC, Chang RC, Lin B, Chung SK, So KF. Protection of retinal ganglion cells and retinal vasculature by Lycium barbarum polysaccharides in a mouse model of acute ocular hypertension[J].PLoS One, 2012, 7(10): e45469.  
52Chen DF, Cho KS. Optic neuropathy and ganglion cell degeneration in glaucoma: mechanisms and therapeutic strategies. In: Tombran-Tink J, Barnstable CJ, Shields MB. Mechanisms of the glaucomas: disease processes and therapeutic modalities[M]. Totowa: Humana Press, 2008. 393-423.  
53Peng Y, Ma C, Li Y, Leung KS, Jiang ZH, Zhao Z. Quantification of zeaxanthin dipalmitate and total carotenoids in Lycium fruits (Fructus Lycii)[J].Plant Foods Hum Nutr, 2005, 60(4): 161-164.  
54Benzie IF, Chung WY, Wang J, Richelle M, Bucheli P. Enhanced bioavailability of zeaxanthin in a milk-based formulation of wolfberry (Gou Qi Zi; Fructus barbarum L.)[J].Br J Nutr, 2006, 96(1): 154-160.  
55Llansola M, Erceg S, Hernandez-Viadel M, Felipo V. Prevention of ammonia and glutamate neurotoxicity by carnitine: molecular mechanisms[J].Metab Brain Dis, 2002, 17(4): 389-397.  
56Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia[J].Cochrane Database Syst Rev, 2009, (1): CD003120.  
57DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications[J].Curr Drug Targets, 2000, 1(1): 25-58.  
58Chung SY, Cheng FC, Lee MS, Lin JY, Lin MC, Wang MF. Ginkgo biloba leaf extract (EGb761) combined with neuroprotective agents reduces the infarct volumes of gerbil ischemic brain[J].Am J Chin Med, 2006, 34(5): 803-817.  
59Chung HS, Harris A, Kristinsson JK, Ciulla TA, Kagemann C, Ritch R. Ginkgo biloba extract increases ocular blood flow velocity[J].J Ocul Pharmacol Ther, 1999, 15(3): 233-240.  
60Park JW, Kwon HJ, Chung WS, Kim CY, Seong GJ. Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma[J].Korean J Ophthalmol, 2011, 25(5): 323-328.  
61Domoráková I, Mechírová E, Danková M, Danielisová V, Burda J. Effect of antioxidant treatment in global ischemia and ischemic postconditioning in the rat hippocampus[J].Cell Mol Neurobiol, 2009, 29(6-7): 837-844.  
62Nada SE, Shah ZA. Preconditioning with Ginkgo biloba (EGb 761?) provides neuroprotection through HO1 and CRMP2[J].Neurobiol Dis, 2012, 46(1): 180-189.  
63Saleem S, Zhuang H, Biswal S, Christen Y, Doré S. Ginkgo biloba extract neuroprotective action is dependent on heme oxygenase 1 in ischemic reperfusion brain injury[J].Stroke, 2008, 39(12): 3389-3396.  
64Shah ZA, Nada SE, Doré S. Heme oxygenase 1, beneficial role in permanent ischemic stroke and in Gingko biloba (EGb 761) neuroprotection[J].Neuroscience, 2011, 180: 248-255.  
65Mdzinarishvili A, Sumbria R, Lang D, Klein J. Ginkgo extract EGb761 confers neuroprotection by reduction of glutamate release in ischemic brain[J].J Pharm Pharm Sci, 2012, 15(1): 94-102.  
66Flammer J, Mozaffarieh M. What is the present pathogenetic concept of glaucomatous optic neuropathy? Surv Ophthalmol. 2007; 52 (Suppl 2): S162-S173.
67Koh PO. Gingko biloba extract (EGb 761) prevents increase of Bad-Bcl-XL interaction following cerebral ischemia[J].Am J Chin Med, 2009, 37(5): 867-876.  
68Smith JV, Burdick AJ, Golik P, Khan I, Wallace D, Luo Y. Anti-apoptotic properties of Ginkgo biloba extract EGb 761 in differentiated PC12 cells[J].Cell Mol Biol (Noisy-le-grand), 2002, 48(6): 699-707.  
69Khoury R, Cross JM, Girkin CA, Owsley C, McGwin G Jr. The association between self-reported glaucoma and Ginkgo biloba use[J].J Glaucoma, 2009, 18(7): 543-545.  
70Hirooka K, Tokuda M, Miyamoto O, Itano T, Baba T, Shiraga F. The Ginkgo biloba extract (EGb 761) provides a neuroprotective effect on retinal ganglion cells in a rat model of chronic glaucoma[J].Curr Eye Res, 2004, 28(3): 153-157.  
 Home | Current Issue | Past Issues | SearchRSS
Copyright © 2013-2018 by JIM Editorial Office. All rights reserved. ISSN 2095-4964; CN 31-2083/R. 沪ICP备110264号